Related Experiment Videos
Epidermal growth factor receptor: a promising target in solid tumours.
Janessa J Laskin1, Alan B Sandler
1Division of Medical Oncology, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada. jlaskin@bccancer.bc.ca
Cancer Treatment Reviews
|February 10, 2004
Summary
Targeting the epidermal growth factor receptor (EGFR) shows promise in treating solid tumors. EGFR blockade therapies, including antibodies and kinase inhibitors, are effective and well-tolerated, warranting further clinical investigation.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Epidermal growth factor receptor (EGFR) is prevalent in various solid tumors.
- EGFR signaling pathways are crucial in cancer development and progression.
- Targeting intracellular signaling cascades is a key strategy in molecular-targeted cancer therapy.
Purpose of the Study:
- To review current inhibitory strategies targeting EGFR.
- To evaluate the efficacy and tolerability of EGFR blockade in preclinical and clinical settings.
Main Methods:
- Review of preclinical studies and clinical trials on EGFR-targeted therapies.
- Analysis of various inhibitory strategies, including monoclonal antibodies and tyrosine kinase inhibitors.
Main Results:
- Multiple EGFR-targeted strategies demonstrate efficacy against EGFR-expressing tumor cells in preclinical models.
- Clinical trials indicate that monoclonal antibody blockade and EGFR tyrosine kinase inhibitors are generally well-tolerated and effective.
Conclusions:
- EGFR blockade represents a promising therapeutic approach for solid tumors.
- Further clinical trials are necessary to establish the optimal role of EGFR-targeted agents in cancer care.